TY  - BOOK
AU  - Sugarbaker, Paul H
TI  - Peritoneal Carcinomatosis of Urachus Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An International Registry of 36 Patients
SN  - 1068-9265
PY  - 2018///
KW  - *Antineoplastic Combined Chemotherapy Protocols/tu [Therapeutic Use]
KW  - *Chemotherapy, Cancer, Regional Perfusion/mo [Mortality]
KW  - *Cytoreduction Surgical Procedures/mo [Mortality]
KW  - *Hyperthermia, Induced/mo [Mortality]
KW  - *Neoplasm Recurrence, Local/th [Therapy]
KW  - *Peritoneal Neoplasms/th [Therapy]
KW  - *Urachus/pa [Pathology]
KW  - Adult
KW  - Combined Modality Therapy
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - International Agencies
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Recurrence, Local/pa [Pathology]
KW  - Peritoneal Neoplasms/sc [Secondary]
KW  - Prognosis
KW  - Prospective Studies
KW  - Registries
KW  - Retrospective Studies
KW  - Survival Rate
KW  - Young Adult
KW  - Washington Cancer Institute
KW  - Journal Article
N1  - Available online from MWHC library: 1994 - present
N2  - CONCLUSION: CRS and HIPEC may increase long-term survival in selected patients with peritoneal metastases of urachus origin, especially when complete CRS is achieved; METHODS: A prospective multicenter international database was retrospectively searched to identify all patients with urachus tumor and peritoneal metastases who underwent CRS and HIPEC through the Peritoneal Surface Oncology Group International (PSOGI). Postoperative complications, long-term results, and principal prognostic factors were analyzed; PURPOSE: Peritoneal carcinomatosis or pseudomyxoma peritonei from urachus is a rare form of presentation, often diagnosed at an advanced state of tumor burden. Because of its rarity, little is known about its natural history, prognosis, or optimal treatment. We searched a large international multicenter database of peritoneal surface disease to identify cases of peritoneal carcinomatosis of urachus that were treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) at expert centers. The aim is to improve knowledge and understanding of the disease and standardize its treatment; RESULTS: The analysis included 36 patients. After median follow-up of 48 months, median overall survival (OS) was 58.5 months. Three- and 5-year OS was 55.4 and 46.2%, respectively. Patients who underwent complete macroscopic CRS had significantly better survival than those treated with incomplete CRS, with median OS not achieved and of 20.1 months, respectively [95% confidence interval (CI) 4.4-30.5, p < 0.001]. There were no postoperative deaths, and 37.9% of patients had major complications
UR  - https://dx.doi.org/10.1245/s10434-017-6299-z
ER  -